One of the many challenges of going in new directions with targeting proteins in a totally different therapy area is things do not always progress as expected or hoped.

For some the journey is a smooth one, for others the path to success can be considerably bumpier.

In today’s story we look at different examples in the context of how drugs originally developed in oncology may also potentially have a key role to play in metabolic diseases.

Going from preclinical to clinical development is never easy, as these examples illustrate…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by